Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Hydralazine on Alzheimer’s disease
IRCT20200711048075N1Phase 3Completed
- Sponsor
- NIMAD
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of hydralazine in Alzheimer's disease (AD), sponsored by NIMAD. Started Sep 2020; status: completed.
02
Drugs
hydralazine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on IRCT20200711048075N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200711048075N1.